Psychemedics Corporation (NASDAQ:PMD) VP Michael I. Schaffer sold 981 shares of Psychemedics Corporation stock in a transaction on Friday, September 1st. The stock was sold at an average price of $21.16, for a total transaction of $20,757.96. Following the completion of the transaction, the vice president now directly owns 41,273 shares of the company’s stock, valued at approximately $873,336.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Psychemedics Corporation (PMD) traded down 2.96% during trading on Friday, reaching $18.69. 61,529 shares of the company’s stock were exchanged. The stock’s 50-day moving average price is $21.97 and its 200-day moving average price is $21.61. The company has a market capitalization of $102.63 million, a price-to-earnings ratio of 13.79 and a beta of 1.02. Psychemedics Corporation has a 52-week low of $13.81 and a 52-week high of $27.99.

Psychemedics Corporation (NASDAQ:PMD) last issued its earnings results on Wednesday, August 2nd. The company reported $0.16 EPS for the quarter. The business had revenue of $9.68 million during the quarter. Psychemedics Corporation had a return on equity of 47.94% and a net margin of 17.59%. Equities analysts expect that Psychemedics Corporation will post $0.93 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, August 24th. Investors of record on Monday, August 14th were paid a $0.15 dividend. The ex-dividend date of this dividend was Thursday, August 10th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 3.21%. Psychemedics Corporation’s payout ratio is 44.44%.

WARNING: “Psychemedics Corporation (PMD) VP Sells $20,757.96 in Stock” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/09/09/psychemedics-corporation-pmd-vp-sells-20757-96-in-stock.html.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Mountain Capital Investment Advisors Inc acquired a new position in shares of Psychemedics Corporation in the second quarter valued at $136,000. Connors Investor Services Inc. raised its stake in shares of Psychemedics Corporation by 13.3% in the second quarter. Connors Investor Services Inc. now owns 11,902 shares of the company’s stock valued at $297,000 after purchasing an additional 1,400 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Psychemedics Corporation by 14.2% in the second quarter. Janney Montgomery Scott LLC now owns 14,218 shares of the company’s stock valued at $355,000 after purchasing an additional 1,767 shares in the last quarter. Carl Domino Inc raised its stake in shares of Psychemedics Corporation by 0.6% in the second quarter. Carl Domino Inc now owns 14,485 shares of the company’s stock valued at $361,000 after purchasing an additional 92 shares in the last quarter. Finally, Gs Investments Inc. acquired a new position in shares of Psychemedics Corporation in the second quarter valued at $387,000. Institutional investors and hedge funds own 57.93% of the company’s stock.

Psychemedics Corporation Company Profile

Psychemedics Corporation (Psychemedics) provides hair testing for drugs of abuse, utilizing a hair analysis method involving digestion of hair, enzyme immunoassay (EIA) technology and confirmation by mass spectrometry to analyze human hair to detect abused substances. The Company operates in drug testing services segment.

Insider Buying and Selling by Quarter for Psychemedics Corporation (NASDAQ:PMD)

Receive News & Stock Ratings for Psychemedics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psychemedics Corporation and related stocks with our FREE daily email newsletter.